The replies in Michel0220's contribution regarding Jonathan Sackner Bernstein's theory on dopamine restriction naturally pertain to the video. However, I am missing the scientific basis for this. It can be found in JSB’s recent article in the Journal of Neurology. While it is somewhat understandable, it is challenging for me as a layperson to critically assess the supporting evidence for his theory. As I mentioned in my reply to the video, I have become more positive about his claims based on my own experience of gradually reducing my high dosage of L/C to zero over the course of a year and a half. This was not my goal as a fan of Sinemet, but rather because I found that I needed less of it over time. There seemed to be some sort of interaction between the use of C/L and my approach to managing PD symptoms. In doing so, I encountered the phenomenon that JSB mentioned, which seems to contradict the existing understanding among medical professionals who have been taught that PD always involves an increase in L/C dosage, at most maintaining a status quo for a certain period. My neurologist somewhat coerced me into taking higher doses of L/C again, as he believed I would eventually need it in the near future. Naturally, I refused.
On the other hand, I also read here on HU about many PWPers who have been functioning well on Sinemet for as long as 20 years or even more. The studies on C/L usage may only cover a maximum of 40 weeks, but JSB’s discussion of the well-known long-term application of this drug remains underemphasized. Nevertheless, there are many issues associated with prolonged C/L usage, perhaps even the base of existence of this forum...
Among you, there are undoubtedly those who can take a more scientific perspective on the article and consider the possible implications of his Dopamine Reduction Therapy and the use of the drug metyrosine (RB-190).
Abstract
Following reports of low striatal dopamine content in Parkinson’s disease, levodopa was shown to rapidly reverse hypokinesis, establishing the model of disease as one of dopamine deficiency. Dopaminergic therapy became standard of care, yet it failed to reverse the disease, suggesting the understanding of disease was incomplete. The literature suggests the potential for toxicity of dopamine and its metabolites, perhaps more relevant given the recent evidence for elevated cytosolic dopamine levels in the dopaminergic neurons of people with Parkinson’s. To understand the relevance of these data, multiple investigations are reviewed that tested dopamine reduction therapy as an alternative to dopaminergic agents. The data from use of an inhibitor of dopamine synthesis in experimental models suggest that such an approach could reverse disease pathology, which suggests that cytosolic dopamine excess is a primary driver of disease. These data support clinical investigation of dopamine reduction therapy for Parkinson’s disease. Doing so will determine whether these experimental models are predictive and this treatment strategy is worth pursuing further. If clinical data are positive, it could warrant reconsideration of our disease model and treatment strategies, including a shift from dopaminergic to dopamine reduction treatment of the disease.
The complete text: